Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas

Journal of Immunology

Volumn 163, Issue 2, 1999, Pages 1037-1044

  Rongcun, Yang ^a,b   Salazar Onfray, Flavio ^a,b   Charo, Jehad ^a,b   Malmberg, Karl Johan ^a,b   Evrin, Kristina ^a,b   Maes, Hubert ^a,b   Kono, Koji ^a,c   Hising, Christina ^a   Petersson, Max ^a,b   Larsson, Olle ^a   Lan, Li ^a,b   Appella, Ettore ^d   Sette, Alessandro ^e   Celis, Esteban ^e,f   Kiessling, Rolf ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Epimmune   (United States)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; PEPTIDE;

ANTIGEN BINDING; ARTICLE; ASCITES; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; OVARY CARCINOMA; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; TARGET CELL; TUMOR CELL;

CARCINOMA; CELL SEPARATION; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033565301     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, and C. A. Seipp. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
2. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, and A. B. Deleo. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297.
3. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
4. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
5. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, and J. P. Szikora. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
6. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
7. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
8. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489.
9. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
10. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. 1997. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158:1796.
11. Celis, E., V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, and H. M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105.
12. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181:2109.
13. Yoshino, I., P. S. Goedegebuure, G. E. Peoples, A. S. Parikh, J. M. DiMaio, H. K. Lyerly, A. F. Gazdar, and T. J. Eberlein. 1994. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54:3387.
14. Ioannides, C. G., R. S. Freedman, C. D. Platsoucas, S. Rashed, and Y. P. Kim. 1991. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 146:1700.
15. Peoples, G. E., P. S. Goedegebuure, J. V. Andrews, D. D. Schoof, and T. J. Eberlein. 1993. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J. Immunol. 151:5481.
16. + ovarian cancers. J. Immunol. 152:4993.
17. Coussens, L., T. L. Yang-Feng, Y. C. Liao, E. Chen, A. Gray, J. McGrath, P. H. Seeburg, T. A. Libermann, J. Schlessinger, and U. Francke. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132.
18. Linehan, D. C., P. S. Goedegebuure, G. E. Peoples, S. O. Rogers, and T. J. Eberlein. 1995. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. 155: 4486.
19. Peoples, G. E., P. S. Goedegebuure, R. Smith, D. C. Linehan, I. Yoshino, and T. J. Eberlein. 1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92: 432.
20. Kawashima, I., S. J. Hudson, V. Tsai, S. Southwood, K. Takesako, E. Appella, A. Sette, and E. Celis. 1998. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59:1.
21. Bodey, B., B. Bodey, Jr., A. M. Groger, J. V. Luck, S. E. Siegel, C. R. Taylor, and H. E. Kaiser. 1997. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res. 17:1319.
22. Ioannides, C. G., C. D. Platsoucas, S. Rashed, J. T. Wharton, C. L. Edwards, and R. S. Freedman. 1991. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 51:4257.
23. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.
24. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J. Exp. Med 179:1109.
25. Wasserman, K., M. M. Corsi, L. Szekel, K. Kono, H. H. Maes, and R. Kiessling. 1997. Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-encoded CTL peptide epitope. Scand. J. Immunol. 45:678.
26. Rongcun, Y., H. Maes, M. Corsi, F. Dellner, T. Wen, and R. Kiessling. 1998. Interferon γ impairs the ability of monocyte-derived dendritic cells to present tumor-specific and allo-specific antigens and reduces their expression of CD1 A, CD80 and CD4. Cytokine 10:747.
27. Sette, A., J. Sidney, M. F. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H. M. Grey, and R. T. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31:813.
28. Ruppert, J., J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
29. Zemmour, J., A. M. Little, D. J. Schendel, and P. Parham. 1992. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J. Immunol. 148:1941.
30. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant T×B cell hybrid. EMBO J. 5:943.
31. + T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. Int. J. Cancer 70:112.
32. Kono, K., Y. Rongcun, J. Charo, F. Ichihara, E. Celis, A. Sette, E. Appella, T. Sekikawa, Y. Matsumoto, and R. Kiessling. 1998. Identification of HER2/ neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer 78:202.
33. ras peptide presented by HLA-A*0201. Int. J. Cancer 61:389.
34. Houbiers, J. G., H. W. Nijman, S. H. van der Burg, J. W. Drijfhout, P. Kenemans, C. J. van de Velde, A. Brand, F. Momburg, W. M. Kast, and C. J. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072.
35. Brossart, P., G. Stuhler, T. Rad, S. Stevanovic, H. G. Rammensee, L. Kanz, and W. Brugger. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732.
36. Peiper, M., P. S. Goedegebuure, D. C. Linehan, E. Ganguly, C. C. Douville, and T. J. Eberlein. 1997. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur. J. Immunol. 27:1115.
37. Torre, E. A., V. Salimbeni, and R. A. Fulco. 1997. The erbB 2 oncogene and chemotherapy: a mini-review. J. Chemother. 9:51.
38. Salazar-Onfray, F., T. Nakazawa, V. Chhajlani, M. Petersson, K. Karre, G. Masucci, E. Celis, A. Sette, S. Southwood, E. Appella, and R. Kiessling. 1997. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res. 57:4348.
39. Xia, Y., R. Muceniece, and J. E. Wikberg. 1996. Immunological localization of melanocortin 1 receptor on the cell surface of WM266-4 human melanoma cells. Cancer Lett. 98:157.
40. Peoples, G. E., D. D. Schoof, J. V. Andrews, P. S. Goedegebuure, and T. J. Eberlein. 1993. T-cell recognition of ovarian cancer. Surgery 114:227.